Treatment of dyskinesia

Abstract

The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.

1 . The use of a compound which inhibits selectively mu opioid receptor activity, or activation, for the manufacture of a medicament for the treatment of dyskinesia  
     
     
         2 . The use according to  claim 1 , wherein the compound is a mu opioid receptor antagonist.  
     
     
         3 . The use according to  claim 2 , wherein the antagonist is a selective mu opioid receptor antagonist selected from the group consisting of Clocinnamox, Etonitazenyl isothiocyanate, β-funaltrexamine, naloxonazine or cyprodime.  
     
     
         4 . The use according to  claim 3 , wherein the antagonist is cyprodime.  
     
     
         5 . The use according to  claim 4 , for administration to a subject in need of treatment at a dose of cyprodime of between 0.1 mgs/kg/day and 500 mgs/kg/day.  
     
     
         6 . The use according to  claim 5 , for administration to a subject in need of treatment at a dose of cyprodime of between 0.3 mgs/kg/day and 100 mgs/kg/day.  
     
     
         7 . The use according to  claim 6 , for administration to a subject in need of treatment at a dose of cyprodime of about 10 mgs/kg/day.  
     
     
         8 . The use according to any preceding claim, for the treatment of dyskinesia associated with movement disorders.  
     
     
         9 . The use according to  claim 8 , for the treatment of dyskinesia associated with parkinsonism.  
     
     
         10 . The use according to  claim 9  wherein the parkinsonism is idiopathic Parkinson's disease or post-encephalitic parkinsonism.  
     
     
         11 . The use according to  claim 9  wherein the parkinsonism results from head injury, the treatment of schizophrenia, drug intoxication or manganese poisoning.  
     
     
         12 . The use according to any one of claims  1 - 7  for the treatment of dyskinesia associated with Huntington's disease, idiopathic torsion dystonia, tardive dyskinesia or off-dystonia in Parkinson's disease.  
     
     
         13 . The use according to any one of claims  1 - 7  for the treatment of dyskinesia which arises a side-effect of a therapeutic agent.  
     
     
         14 . The use according to  claim 13  for the treatment of dyskinesia associated with agents used to treat movement disorders.  
     
     
         15 . The use according to  claim 13  or  14  wherein the agent is L-DOPA or apomorphine.  
     
     
         16 . The use according to  claim 15  wherein the L-DOPA or apomorphine is used to treat parkinsonism.  
     
     
         17 . The use according to any preceding claim, wherein the medicament is in the form of any one of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micelle, or liposome.  
     
     
         18 . The use according to any preceding claim wherein the medicament is for oral administration.  
     
     
         19 . The use according to any preceding claim for prophylactic treatment of dyskinesia.  
     
     
         20 . A method for the treatment of dyskinesia comprising administering to a person or animal in need of such treatment a therapeutically effective amount of a compound which inhibits selectively mu opioid receptor activity or activation.  
     
     
         21 . The method according to claim  20  comprising administering a compound as defined in any one of  claims 1  to  19 .